Inhibition of the myocardial Ca2+ inward current by the class 1 antiarrhythmic agent, cibenzoline
- PMID: 3708204
- PMCID: PMC1916814
- DOI: 10.1111/j.1476-5381.1986.tb14588.x
Inhibition of the myocardial Ca2+ inward current by the class 1 antiarrhythmic agent, cibenzoline
Abstract
Cibenzoline, a class 1 (local anaesthetic-type) antiarrhythmic drug, was investigated for possible effects upon the myocardial Ca2+ inward current. In voltage-clamp experiments with isolated cardiac myocytes of guinea-pig, cibenzoline caused a concentration-dependent inhibition of the Ca2+ current, with an IC50 of 14 microM. Inhibition of the Ca2+ current by cibenzoline (2 microM) was dependent upon stimulation frequency, with a greater block occurring at 2 Hz (approximately 50%) than at 0.2 Hz (approximately 15%). The magnitude of Ca2+ current block was also potential-dependent. A markedly greater inhibition by cibenzoline (20 microM) was recorded when myocytes were depolarized (to +20 mV) from a holding potential of -35 mV than of -80 mV. At the less negative potential, cibenzoline also caused a reduction in the level of the holding current, which suggests a decrease in the inwardly rectifying K+ current. Cibenzoline also caused a concentration-dependent inhibition of KCl-induced contractures of isolated aortic strips of the rat (IC50 = 55 microM) and a reduction in contractile force of isolated, electrically-stimulated papillary muscles of the guinea-pig (IC50 = 35 microM). Thus, cibenzoline possesses Ca2+ channel blocking (class 4) properties in addition to its local anaesthetic actions.
Similar articles
-
Comparison of Ca2+ channel inhibitory effects of cibenzoline with verapamil on guinea-pig heart.Gen Pharmacol. 1991;22(1):87-91. doi: 10.1016/0306-3623(91)90314-v. Gen Pharmacol. 1991. PMID: 2050292
-
Na+ channel blocking effects of cibenzoline on guinea-pig ventricular cells.Eur J Pharmacol. 1998 Jul 10;352(2-3):317-27. doi: 10.1016/s0014-2999(98)00354-9. Eur J Pharmacol. 1998. PMID: 9716369
-
Comparative studies of ATP sensitive potassium channels in heart and pancreatic beta cells using Vaughan-Williams class Ia antiarrhythmics.Cardiovasc Res. 1992 Nov;26(11):1087-94. doi: 10.1093/cvr/26.11.1087. Cardiovasc Res. 1992. PMID: 1291086
-
Effects of cibenzoline, a new class Ia antiarrhythmic drug, on various membrane ionic currents and action potentials of guinea-pig ventricular cells.Naunyn Schmiedebergs Arch Pharmacol. 1994 Aug;350(2):167-73. doi: 10.1007/BF00241092. Naunyn Schmiedebergs Arch Pharmacol. 1994. PMID: 7527502
-
The current status of the mechanism of the calcium channel antagonists.Prog Cardiovasc Dis. 1982 Sep-Oct;25(2):133-40. doi: 10.1016/0033-0620(82)90024-x. Prog Cardiovasc Dis. 1982. PMID: 7051137 Review. No abstract available.
Cited by
-
Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy.Heart Vessels. 2006 Nov;21(6):350-5. doi: 10.1007/s00380-006-0917-1. Epub 2006 Nov 27. Heart Vessels. 2006. PMID: 17143709
-
Pharmacological cardioversion of atrial fibrillation: current management and treatment options.Drugs. 2004;64(24):2741-62. doi: 10.2165/00003495-200464240-00003. Drugs. 2004. PMID: 15563247 Review.
-
Inhibition of the ATP-sensitive potassium channel by class I antiarrhythmic agent, cibenzoline, in rat pancreatic beta-cells.Br J Pharmacol. 1993 Aug;109(4):1226-31. doi: 10.1111/j.1476-5381.1993.tb13753.x. Br J Pharmacol. 1993. PMID: 8401933 Free PMC article.
-
Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias.Drugs. 1992 May;43(5):734-59. doi: 10.2165/00003495-199243050-00008. Drugs. 1992. PMID: 1379150 Review.
-
Cibenzoline, an ATP-sensitive K(+) channel blocker, binds to the K(+)-binding site from the cytoplasmic side of gastric H(+),K(+)-ATPase.Br J Pharmacol. 2001 Dec;134(8):1655-62. doi: 10.1038/sj.bjp.0704422. Br J Pharmacol. 2001. PMID: 11739241 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous